United States. Securities and Exchange Commission

Stock offerings

II-VI Incorporated Commences Concurrent Underwritten Public Offerings of Common Stock and Series A Mandatory Convertible Preferred Stock

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, has initiated concurrent underwritten public offerings of $350.0 million of newly issued shares of its common stock and $400.0 million aggregate liquidation preference of a newly established Series A Mandatory Convertible Preferred Stock. The offerings are subject

United States. Securities and Exchange Commission

Portola Pharmaceuticals Receives Notice of Termination for Clinical Collaboration Agreement with Bayer

Portola Pharmaceuticals, Inc. recently received written notice of termination from Bayer AG for a Clinical Collaboration Agreement dated February 1, 2016. This termination allows Portola to regain full rights in Japan for the development and commercialization of andexanet alfa, a reversal agent for Factor Xa inhibitors. The notice was given